Lymphocyte-Associated Inflammation Markers Predict Bleomycin-Induced Pulmonary Toxicity in Testicular Cancer

<b>Introduction:</b> It is unclear which patients with testicular cancer (TC) experience a higher incidence of bleomycin-induced pulmonary toxicity. <b>Objective:</b> The aim of this study was to analyze the prognostic significance of lymphocyte-associated inflammation markers that may predict bleomycin-related pulmonary toxicity in TC. <b>Results:</b> Clinical and laboratory data were recorded for 118 patients diagnosed with TC who received bleomycin, with a median age at diagnosis of 32.19 ± 9.62. Symptomatic pulmonary toxicity was present in 19.49% (n = 23) of patients. Of these, 66.67% had a DLCO decrease of more than 10%. When comparing patients with and without pulmonary toxicity, there were no differences in terms of age at diagnosis, performance status, histopathological subgroup, tumor size, lymphovascular invasion, diagnostic symptom, stage, number of adjuvant treatment cycles, and tumor marker levels. Patients with pulmonary toxicity were more likely to be active smokers than those without pulmonary toxicity, and NLR > 1.64, PLR > 93.92, CLR > 0.49, SII > 444.25, and SIRI > 0.66 were found to be statistically significant. Lymphocyte-related inflammation markers (NLR, PLR, LMR, CLR, SII, and SIRI) were found to be prognostic for pulmonary toxicity. There was 5.2 times more pulmonary toxicity in smokers than in non-smokers. The prognostic inflammation markers that enable us to predict pulmonary toxicity are TC. <b>Conclusions:</b> The employment of lymphocyte-related inflammation biomarkers at the commencement of treatment offers a means of predicting bleomycin-related pulmonary toxicity in TC.